UBS raises target for Monte Rosa stock from USD 17 to USD 19

Published on 10/14/2026 at 02:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LifeSci kept Buy on Monte Rosa stock on October 3, 2026. Second-quarter revenue was USD 8.97 million and GAAP net loss USD 43.40 million.

Analyst targets and clinical timing

UBS lifted its Monte Rosa target from USD 17.00 to USD 19.00 on October 11, 2026.
Second-quarter 2026 revenue was USD 8.97 million, while GAAP net loss reached USD 43.40 million.
Monte Rosa expects the GEMINI-1 Phase 2 study to begin in the fourth quarter of 2026 or first quarter of 2027.

GLUE, US61225M1027, Illustration mit AI erstellt.

UBS raised its price target for Monte Rosa Therapeutics stock from USD 17.00 to USD 19.00 on October 11, 2026, while keeping a Buy rating, according to Markets Insider. The revision puts the latest analyst action alongside Monte Rosa's early clinical data and substantial development spending.

Chronology of key milestones

On September 8, 2026, Monte Rosa reported that Novartis had started a Phase 2 study of MRT-6160, triggering a USD 50.00 million milestone payment, according to StockTitan. On September 30, the company scheduled an October 1 presentation for MRT-8102 data at 8:00 a.m. ET, as stated in its investor-relations release. On October 1, the GFORCE-1 Phase 1 study reported data from 108 participants, with median NEK7 degradation of 80.00 percent to 90.00 percent, according to Monte Rosa Therapeutics.

What does the study show

The October 1 results also showed median reductions of 85.00 percent in hsCRP and 24.00 percent in lipoprotein(a), while treatment-emergent adverse events occurred in 33.00 percent of MRT-8102 participants and 30.00 percent of placebo participants. No serious adverse events were reported in the four-week treatment period and four-week follow-up, according to Monte Rosa Therapeutics.

The financial counterweight is material. Monte Rosa reported USD 8.97 million of revenue and a USD 43.40 million GAAP net loss for the second quarter of 2026, compared with USD 23.19 million of revenue and a USD 12.30 million GAAP net loss in the second quarter of 2025, according to Markets Insider. The figures show why clinical progress and cash use remain linked in the valuation debate.

Upcoming clinical dates

Monte Rosa expects the GEMINI-1 Phase 2 study in gout to begin in the fourth quarter of 2026 or first quarter of 2027, with initial data expected in the second half of 2027. The company expects GFORCE-2 in coronary artery disease and GALAXY-1 in hidradenitis suppurativa to begin in the first half of 2027, according to Monte Rosa Therapeutics.

Nasdaq context for GLUE

Monte Rosa Therapeutics was last quoted at USD 9.89 on Nasdaq on October 13, 2026 at 4:00 p.m. ET. The company had a market capitalization of USD 835.5 million and a 52-week Nasdaq range of USD 8.94 to USD 25.77 as of the same market-data snapshot.